Related references
Note: Only part of the references are listed.AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis
J. Hercogova et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
Nam Hee Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2019)
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
G. L. Goll et al.
JOURNAL OF INTERNAL MEDICINE (2019)
Effectiveness of Infliximab Biosimilar in Crohn’s Disease: A Dime, A Dozen
Gionata Fiorino et al.
GASTROENTEROLOGY (2019)
Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis Fifty-Two-Week Phase III Randomized Study Results
Michael E. Weinblatt et al.
ARTHRITIS & RHEUMATOLOGY (2018)
The nocebo effect: a clinical challenge in the era of biosimilars
Lieven Pouillon et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Patent expiry dates for biologicals: 2017 update
Michelle Derbyshire
GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL (2018)
Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review
Massimo Radin et al.
BIODRUGS (2017)
ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update
Silvio Danese et al.
JOURNAL OF CROHNS & COLITIS (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Assays for measurement of TNF antagonists in practice
Niels Vande Casteele
FRONTLINE GASTROENTEROLOGY (2017)
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
Stanley Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre
M. Kolar et al.
DIGESTIVE DISEASES (2017)
Pain perception after subcutaneous injections of media containing different buffers
T Laursen et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2006)
Share Paper
